Illumina, Inc. (ILMN) Expands Product Portfolio To Support Oncology Clinical Research And Discovery
4/2/2014 9:28:13 AM
SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ:ILMN) today announced new products that can be applied directly to the discovery and translation of genomic variation in blood and tissue associated with cancer. The expanded portfolio leverages the company’s industry-leading next-generation sequencing (NGS) and microarray scanning systems to deliver sample-to-data solutions for basic and clinical cancer research.
Help employers find you! Check out all the jobs and post your resume.
comments powered by